Prostate Cancer News and Research RSS Feed - Prostate Cancer News and Research Twitter

Prostate cancer is the most common non-skin cancer in the United States and the third most common cancer worldwide. More than 1 million men in the United States have prostate cancer and it is the second leading cause of cancer death amongst men after lung cancer. In 2009, an estimated 192,280 new cases are expected to be diagnosed and approximately 27,360 men are expected to die from the disease. Castration-resistant prostate cancer (CRPC) is defined as prostate cancer that continues to grow despite all standard-of-care hormonal (anti-androgen) therapies. Patients with castration-resistant (also known as hormone-refractory) prostate cancer have few treatment options and a poor prognosis.
Further Reading
VolitionRx initiates study to assess NuQ blood tests for detection of prostate cancer

VolitionRx initiates study to assess NuQ blood tests for detection of prostate cancer

VolitionRx Limited today announced that it has initiated a study to assess the feasibility of using the Company’s NuQ blood tests to detect prostate cancer. The study is in collaboration with the Surrey Cancer Research Institute of the University of Surrey in the UK. [More]
Bowel Cancer UK's new landmark study aims to identify critical gaps in current bowel cancer research

Bowel Cancer UK's new landmark study aims to identify critical gaps in current bowel cancer research

Bowel Cancer UK is announcing on World Cancer Day (Thursday 4 February) a new research project which will bring together 100 clinicians and scientists to identify gaps in current research into bowel cancer which, if addressed, will help save the lives of thousands of people diagnosed with the disease. [More]
Molecular imaging and radiochemistry: the importance of instrumentation. An interview with Professor Björn Wängler

Molecular imaging and radiochemistry: the importance of instrumentation. An interview with Professor Björn Wängler

I’m Björn Wängler, Professor for Molecular Imaging and Radiochemistry at the medical faculty Mannheim of Heidelberg University. I’m a radiopharmaceutical chemist by background and completed my PhD in 2004 at the University of Mainz. [More]
NICE recommends Xofigo (radium-223 dichloride) for prostate cancer patients after treatment with docetaxel

NICE recommends Xofigo (radium-223 dichloride) for prostate cancer patients after treatment with docetaxel

The National Institute for Health and Care Excellence has issued its final guidance recommending Xofigo for use on the NHS in England and Wales as an option for treating adult men, with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastases, who have received previous docetaxel therapy. [More]
New biosensor test system developed for accurate measurements of protein molecule concentration in blood

New biosensor test system developed for accurate measurements of protein molecule concentration in blood

Researchers from the General Physics Institute of the Russian Academy of Sciences and Moscow Institute of Physics and Technology have developed a new biosensor test system based on magnetic nanoparticles. [More]
NJHF awards 30 grants for NJ researchers working on health-related research

NJHF awards 30 grants for NJ researchers working on health-related research

New Jersey Health Foundation has awarded 30 grants totaling more than $1 million for researchers in New Jersey who are working on health-related research that demonstrates exciting potential. [More]
Scientific breakthrough could contribute to early diagnosis of osteoporosis, Alzheimer's

Scientific breakthrough could contribute to early diagnosis of osteoporosis, Alzheimer's

Scientists from the University of Granada have developed a new fluorescent dye capable of detecting, in a single test lasting 20 minutes, the presence of phosphate and biothiol inside living cells. This scientific breakthrough could contribute significantly to the early diagnosis of diseases such as osteoporosis, Alzheimer's, type 2 diabetes, and prostate cancer, since abnormal levels of both substances are associated with these diseases. [More]
Sphingosine kinase inhibitor slows castration-resistant prostate cancer cell growth

Sphingosine kinase inhibitor slows castration-resistant prostate cancer cell growth

A first-in-class sphingosine kinase 2 inhibitor slowed the growth of castration-resistant prostate cancer cells, in part by inhibiting the enzyme dihydroceramide desaturase (DEGS), but did not kill them, according to the results of preclinical in vitro and in vivo studies published in the December 2015 issue of Molecular Cancer Therapeutics by researchers at the Medical University of South Carolina and others. [More]
New prognostic biomarker may help determine risk of prostate cancer-related death

New prognostic biomarker may help determine risk of prostate cancer-related death

Researchers at the University of Copenhagen have identified a new prognostic biomarker: the neuropeptide pro-NPY, which may help determine the risk of dying from prostate cancer. This particular type of protein is very specific to prostate cancer cells and could help identify whether newly diagnosed patients require radical prostatectomy surgery or if it is safe to delay surgery. [More]
Newly drafted consensus statement promotes widespread use of HPV vaccines to prevent cancer

Newly drafted consensus statement promotes widespread use of HPV vaccines to prevent cancer

Leaders of several cancer centers designated by the National Cancer Institute have united to support human papillomavirus vaccination. Among them is Cheryl Willman, MD, Director and CEO of the University of New Mexico Comprehensive Cancer Center. [More]
A more effective method for detecting metastatic prostate cancer

A more effective method for detecting metastatic prostate cancer

Conventional imaging methods have limited sensitivity for detecting metastatic prostate cancer. With appropriate, timely treatment vital to survival and quality of life, better imaging has been an ongoing goal. [More]
Nutrition and breast cancer; starving triple negative breast cancer cells to death: an interview with Associate Professor Jeff Holst

Nutrition and breast cancer; starving triple negative breast cancer cells to death: an interview with Associate Professor Jeff Holst

While there are a range of reports that different foods and food groups can increase or decrease your risk of cancer, these associations are very difficult to scientifically verify. [More]
Results from STRIVE trial of enzalutamide versus bicalutamide in CRPC published in Journal of Clinical Oncology

Results from STRIVE trial of enzalutamide versus bicalutamide in CRPC published in Journal of Clinical Oncology

Astellas US LLC, a United States (U.S.) subsidiary of Tokyo-based Astellas Pharma Inc., and Medivation, Inc. today announced that results from the STRIVE trial of enzalutamide compared to bicalutamide in men with castration-resistant prostate cancer (CRPC) were published in the Journal of Clinical Oncology. [More]
High intensity focused ultrasound provides important treatment for men with prostate cancer

High intensity focused ultrasound provides important treatment for men with prostate cancer

For the estimated 220,000 men who will be diagnosed with prostate cancer this year, deciding on a method of treatment can be a challenge. Some with early-stage cancer pursue a "wait and watch" option, also called active surveillance, while others with more severe cancer immediately pursue surgery, including prostatectomy (removal of the prostate). [More]
MDxHealth recognized with 2015 Global Frost & Sullivan Award for Technology Innovation

MDxHealth recognized with 2015 Global Frost & Sullivan Award for Technology Innovation

Based on its recent analysis of the prostate cancer diagnostics market, Frost & Sullivan recognizes MDxHealth with the 2015 Global Frost & Sullivan Award for Technology Innovation. To advance molecular diagnostic tests for urological cancers, MDxHealth supplemented its prostate cancer test, ConfirmMDx, with a urine-based "liquid-biopsy" test called SelectMDx. [More]
Prostate cancer patients living in metropolitan areas more likely to be treated with radiation or surgery

Prostate cancer patients living in metropolitan areas more likely to be treated with radiation or surgery

A new study suggests that men with localized prostate cancer living in more highly populated areas are more likely to be treated with surgery or radiation compared to men residing in less populated areas. [More]
OncoGenex provides update on Phase 2 Spruce trial in patients with untreated metastatic NSCLC

OncoGenex provides update on Phase 2 Spruce trial in patients with untreated metastatic NSCLC

OncoGenex Pharmaceuticals, Inc. announced today that data from the Phase 2 Spruce trial evaluating the combination of apatorsen with carboplatin and pemetrexed in patients with untreated metastatic non-small cell lung cancer (NSCLC) did not reach the statistical significance required to demonstrate a progression-free survival (PFS) benefit. [More]
New imaging test detects prostate cancer much better than any other tests in use today

New imaging test detects prostate cancer much better than any other tests in use today

Researchers at Thomas Jefferson University have found the method they developed to image the prostate appears to be much better at detecting prostate cancer than any other test — radiographical, biopsy or blood — in use today. [More]
WASF3 protein appears to be solid target for reducing cancer metastasis

WASF3 protein appears to be solid target for reducing cancer metastasis

A protein that is constantly expressed by cancer cells and quiescent in healthy ones appears to be a solid target for reducing cancer's ability to spread, scientists report. [More]
Study opens new avenues for treatment of prostate cancer in obese patients

Study opens new avenues for treatment of prostate cancer in obese patients

Obesity has direct consequences on health and is associated with the onset of aggressive cancers, but the mechanisms underlying this phenomenon are little known. Researchers from the Institut de Pharmacologie et he Biologie Structurale (CNRS/Université Toulouse III - Paul Sabatier) have recently elucidated one of these mechanisms in prostate cancer, one of the most common cancers in men: in obese patients, the adipose tissue surrounding the prostate gland facilitates the propagation of tumor cells outside the prostate. [More]
Advertisement
Advertisement